On March 31sr, the European Medicines Agency (EMA) published the Draft Guidance of “Guideline on the quality aspects of mRNA vaccines”. The scope of the Guideline is mRNA vaccines against infectious diseases. Other mRNA-based medicinal products are out of scope of this guideline, although relevant parts of this guideline may be applicable to those. It is not intended to address specific requirements for mRNA vaccines to be used in clinical trials, however the scientific principles described may also be applicable during pharmaceutical development.
This guideline addresses the quality aspects of mRNA vaccines. It addresses specific aspects regarding the manufacturing process, characterisation, specifications and analytical control of mRNA vaccines, as well as the definition of starting materials, active substance and finished product for mRNA vaccines.
Please don’t hesitate to reach out if you have any questions or need assistance: [email protected]
Read the whole information here: https://bit.ly/4jhHT4I
